Helicobacter pylori Infections¶
Chapter 168 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- H. pylori colonization is the primary risk factor for peptic ulcer disease and gastric adenocarcinoma, with ~60% prevalence in developing countries vs. <30% in developed nations.
- Non-invasive tests (urea breath test, stool antigen) are preferred for diagnosis, while endoscopic biopsy remains critical for confirming eradication post-treatment.
- First-line treatment regimens include PPI-based triple or quadruple therapies, with resistance to clarithromycin limiting their use in regions with high resistance rates.
- H. pylori eradication is recommended for peptic ulcer disease, MALT lymphoma, and functional dyspepsia in select patients, though asymptomatic carriers generally do not require treatment.
- Long-term follow-up is essential to monitor for complications like gastric cancer, with endoscopy required to confirm ulcer healing and exclude malignancy.
1. DEFINITION & OVERVIEW¶
Helicobacter pylori is a gram-negative spiral bacterium that colonizes the human stomach, causing chronic gastritis and increasing risk for peptic ulcer disease, gastric adenocarcinoma, and MALT lymphoma. It is the most common bacterial pathogen associated with peptic ulcer disease.
Table 168-1: Tests for Helicobacter pylori Detection¶
| TEST | ADVANTAGES | DISADVANTAGES |
|---|---|---|
| Biopsy urease test | Quick, simple | Some commercial tests not fully sensitive before 24 h |
| Histology | May give additional histologic information | Sensitivity dependent on experience and use of special stains |
| Culture | Permits determination of antibiotic susceptibility | Sensitivity dependent on experience |
| Serology | Inexpensive and convenient; not affected by recent antibiotics or PPIs | Less accurate than breath/stool tests |
| 13C urea breath test | Inexpensive and simpler than endoscopy; useful for follow-up | Requires fasting |
| Stool antigen test | Inexpensive and convenient; useful for follow-up in children | Disliked by some cultures |
1.1 Pathogenesis¶
H. pylori induces chronic gastritis through urease-mediated ammonia production, which neutralizes gastric acid. The cagA+ strains are most strongly associated with gastric adenocarcinoma and MALT lymphoma. VacA toxin contributes to epithelial damage and immune evasion.
1.2 Host-Pathogen Interaction¶
Genetic polymorphisms (e.g., IL1B, PSCA) modulate disease risk. Environmental factors like smoking, diet, and socioeconomic status influence disease progression. H. pylori may offer protective effects against GERD and esophageal adenocarcinoma, though evidence is inconclusive.
2. EPIDEMIOLOGY¶
Global prevalence of H. pylori colonization is ~40% of the world population. Prevalence is higher in developing countries (60–80%) than in developed nations (<30%). Risk factors include childhood acquisition, crowding, poor sanitation, and socioeconomic deprivation. Age-related prevalence declines in developed countries due to improved hygiene and antibiotic use.
2.1 Demographics¶
Prevalence varies by region: >60% in Africa, South America, and West Asia; <30% in the US, Europe, and Oceania. In the US, prevalence is ~18% in adults and 14% in children. Acquisition is most common in childhood, with ~70% of duodenal ulcers and 50% of gastric ulcers linked to H. pylori.
2.2 Transmission¶
Humans are the sole reservoir. Transmission occurs via fecal-oral or oral-oral routes, with children acquiring the infection from family members or contaminated environments. H. pylori is easily cultured from vomitus and refluxate but less so from stool.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
H. pylori colonizes the gastric mucosa, inducing chronic inflammation and immune responses. Key virulence factors include the cag pathogenicity island (CagA+ strains) and VacA toxin. The bacterium's urease neutralizes gastric acid, allowing colonization. Persistent infection leads to gastritis, atrophy, metaplasia, and dysplasia, increasing cancer risk.
3.1 Virulence Factors¶
CagA+ strains are most strongly associated with gastric adenocarcinoma and MALT lymphoma. VacA toxin forms pores in epithelial cells, contributing to inflammation and immune evasion. Adhesins like BabA bind to blood group antigens, enhancing colonization.
3.2 Host Genetic Factors¶
Polymorphisms in IL1B, PSCA, and TLR genes modulate disease risk. CagA+ strains increase risk of peptic ulcer and gastric cancer, while VacA polymorphism correlates with ulcer and cancer risk.
4. CLINICAL FEATURES¶
Most H. pylori-colonized individuals are asymptomatic. Symptomatic cases present with dyspepsia, epigastric pain, or upper GI bleeding. Complications include peptic ulcer disease, gastric adenocarcinoma, MALT lymphoma, and GERD-related conditions. Functional dyspepsia may resolve with eradication in 15% of cases.
4.1 Disease Associations¶
H. pylori is the main cause of peptic ulcer disease (70% duodenal, 50% gastric ulcers). It is also linked to gastric adenocarcinoma, MALT lymphoma, and Barrett’s esophagus. Protection against GERD and esophageal adenocarcinoma is debated.
4.2 Complications¶
Chronic gastritis progresses to atrophy, metaplasia, and dysplasia. Gastric cancer arises in atrophic gastritis with hypochlorhydria. MALT lymphoma responds to eradication in ~70% of cases, though differentiation from benign lymphoid hyperplasia is challenging.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses for H. pylori-related symptoms include NSAID-induced ulcers, gastritis from other pathogens, Zollinger-Ellison syndrome, and functional dyspepsia. Non-pylori Helicobacter species may cause similar symptoms but are less common.
5.1 Non- pylori Helicobacter Species¶
Non-pylori species (e.g., H. heilmanii) cause low-grade inflammation and rare disease. They are more common in immunocompromised hosts and may mimic Campylobacter infections.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis uses non-invasive tests (urea breath, stool antigen) or endoscopic biopsy. Serology is less reliable for monitoring treatment success. Endoscopy is required for confirming ulcer healing and excluding malignancy post-eradication.
Table 168-2: Helicobacter pylori Treatment Regimens¶
| REGIMENa (DURATION) | DRUG 1 | DRUG 2 | DRUG 3 | DRUG 4 |
|---|---|---|---|---|
| Regimen 1: OCM (14 days)b | Omeprazole (20 mg bidc) | Clarithromycin (500 mg bid) | Metronidazole (500 mg bid) | |
| Regimen 2: OCA (14 days)b | Omeprazole (20 mg bidc) | Clarithromycin (500 mg bid) | Amoxicillin (1 g bid) | |
| Regimen 3: OBTM (14 days)d | Omepr3 (20 mg bidc) | Bismuth subsalicylate (2 tabs qid) | Tetracycline HCl (500 mg qid) | Metronidazole (500 mg tid) |
| Regimen 4: Concomitant (14 days)e | Omeprazole (20 mg bidc) | Amoxicillin (1 g bid) | Clarithromycin (500 mg bid) | Tinidazole (500 mg bidf) |
| Regimen 5: OAL (10 days)g | Omeprazole (20 mg bidc) | Amoxicillin (1 g bid) | Levofloxacin (500 mg bid or 200 mg bid) |
6.1 Diagnostic Tests¶
Non-invasive tests (urea breath, stool antigen) are preferred for initial diagnosis. Endoscopic biopsy urease test and histology confirm colonization. Culture identifies antibiotic susceptibility.
6.2 Post-Treatment Monitoring¶
Non-invasive tests are preferred for assessing eradication success. Biopsy-based tests may be used if PPIs are discontinued for ≥ 6 weeks. False negatives may occur within 4 weeks of treatment.
7. MANAGEMENT & TREATMENT¶
Treatment involves PPI-based triple or quadruple regimens. Eradication is recommended for peptic ulcer disease, MALT lymphoma, and functional dyspepsia in select patients. Resistance to clarithromycin limits regimen effectiveness in regions with high resistance rates.
7.1 Treatment Algorithms¶
First-line regimens include OCM, OCA, or OBTM. Second-line regimens (e.g., concomitant, OAL) are used if first-line fails. Third-line regimens may involve bismuth-based quadruple therapy or levofloxacin-containing regimens. Endoscopy with culture is required for refractory cases.
7.2 Post-Treatment Monitoring¶
Non-invasive tests (urea breath, stool antigen) assess eradication success. Biopsy-based tests may be used if PPIs are discontinued for ≥ 6 weeks. Follow-up endoscopy is required for gastric ulcers to confirm healing and exclude cancer.
8. PROGNOSIS & COMPLICATIONS¶
H. pylori eradication reduces peptic ulcer recurrence and gastric cancer risk. Complications include gastric adenocarcinoma, MALT lymphoma, and GERD-related conditions. Long-term follow-up is needed for patients with atrophic gastritis or dysplasia.
8.1 Cancer Risk Reduction¶
Eradication reduces gastric cancer risk by ~50% but does not eliminate it. Long-term follow-up is required for patients with atrophic gastritis or dysplasia. Gastric cancer incidence is rising in younger adults, possibly due to H. pylori-negative factors.
8.2 GERD and Esophageal Cancer¶
H. pylori may protect against GERD and esophageal adenocarcinoma, though evidence is conflicting. Lifelong colonization may offer some protection, but this remains uncertain.
9. SPECIAL CONSIDERATIONS¶
H. pylori eradication is recommended for patients with peptic ulcer disease, MALT lymphoma, or functional dyspepsia. Asymptomatic carriers generally do not require treatment. Treatment in pregnancy is avoided unless indicated. Children may benefit from eradication due to higher cancer risk reduction.
9.1 Pregnancy¶
Eradication is avoided in pregnancy unless indicated. First-line regimens use PPIs and amoxicillin, avoiding tetracyclines and metronidazole.
9.2 Pediatrics¶
Children are at higher risk for gastric cancer and benefit from eradication. Treatment is preferred in children with confirmed colonization and symptoms.
10. KEY POINTS & CLINICAL PEARLS¶
- H. pylori is the leading cause of peptic ulcer disease and a major risk factor for gastric cancer. 2. Non-invasive tests (urea breath, stool antigen) are preferred for diagnosis. 3. First-line regimens include PPI-based triple or quadruple therapies. 4. Eradication reduces cancer risk but does not eliminate it. 5. Asymptomatic carriers generally do not require treatment.